Loading...
Symphogen attracts new usd 25 million investment
10-Jan-2006
Advertisement
Symphogen A/S announced the initial closing of a USD 25 million Series D financing at a premium to the last financing round. The financing will be used to carry out clinical trials of Symphogen's first product, anti-RhD for the treatment of idiopathic thrombocytopenic purpura (ITP) and engage in additional partnerships to leverage Symphogen's unique human polyclonal and monoclonal antibody discovery and production capabilities.